|
|
Vol. 16.19 – 10 October, 2025
|
|
|
|
|
|
|
|
Investigators hypothesized that PARP inhibition within six months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer could be effective and improve radiographic progression-free survival when added to standard-of-care treatments. [Nature Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers identified p300/CBP-mediated multisite histone H2B N-terminal acetylation as a defining feature of oncogenic enhanceosomes in androgen receptor-positive prostate cancer.
[Nature Genetics]
|
|
|
|
|
|
Scientists demonstrated that androgen receptor (AR) H875Y specific T cell receptors are highly specific and kill prostate cancer cells presenting AR neo-peptides in vitro and in vivo.
[Cancer Discovery]
|
|
|
|
|
|
Researchers characterize MCL1 in multiple metastatic CRPC biopsy cohorts and patient-derived models, assessing responses to MCL1 inhibition.
[Nature Communications]
|
|
|
|
|
|
Clinical findings revealed a synergistic effect between rs4519489 genotype and NOL10 expression on prostate cancer prognosis and severity.
[Nature Communications]
|
|
|
|
|
|
Investigators reported the preclinical activity of MK-6070 in prostate cancer models, showing high specificity and anti-tumor activity in DLL3-expressing neuroendocrine prostate cancer models both in vitro and in vivo, with T cell activation and tumor infiltration of T cells after treatment. [Molecular Cancer Therapeutics]
|
|
|
|
|
|
|
|
There is growing evidence that physical exercise is associated with epigenetic alterations in prostate tissue, although its consequences on the prostate are yet unknown. Scientists summarize research on the molecular processes and therapeutic applications of exercise in prostate tissue. [Cancer Cell International]
|
|
|
|
|
|
|
|
The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial, a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.
[The Alliance for Clinical Trials in Oncology (EurekAlert)]
|
|
|
|
|
|
Vir Biotechnology, Inc. announced that the first patient has been dosed in Part 3 of the Company’s Phase I clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors. [Vir Biotechnology, Inc.]
|
|
|
|
|
|
|
|
November 5-7, 2025 Singapore
|
|
|
|
|
|
|
|
|
|
|
Indiana University – Indianapolis, Indiana, United States
|
|
|
|
|
|
|
Mayo Clinic – Rochester, Minnesota, United States
|
|
|
|
|
|
|
University College London – London, England, United Kingdom
|
|
|
|
|
|
|
University of Miami Desai Sethi Urology Institute – Miami, Florida, United States
|
|
|
|
|
|
|
Henry Ford Health + Michigan State – Detroit, Michigan, United States
|
|
|
|
|
|